Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Long-lasting clinical benefit of sunitinib malate in the treatment of a case of heavily pre-treated metastatic liposarcoma.

Anticancer research - 1 Mar 2013

Porzio Rosa, Bella Maria Angela, Rossi Giulio, Ardizzoni Andrea

Abstract excerpt

BACKGROUND: Soft tissue sarcomas are a heterogeneous group of malignant neoplasms including several distinct entities with different cell differentiation and clinical prognosis, but which are often treated as a single disease. CASE REPORT: We report the case of a male patient, heavily treated for a metastatic well-differentiated liposarcoma occurring in the left lateral neck. He received radiotherapy and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Indoles
Share to Liposarcoma
Share to Neck

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins c-kit

Share to Pyrroles

Share to Receptors, Platelet-Derived Growth Factor

Share to Sunitinib

Source

Identifiers

PMID: 23482782

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Long-lasting clinical benefit of sunitinib malate in the treatment of a case of heavily pre-treated metastatic liposarcoma.PMID 23482782Read ↗

Genetic, Epigenetic and Transcriptome Alterations in Liposarcoma for Target Therapy SelectionSemantic proximity Read ↗

Targeting liposarcoma: unveiling molecular pathways and therapeutic opportunitiesSemantic proximity Read ↗

Clinical and Molecular Spectrum of LiposarcomaSemantic proximity Read ↗

Targeting MCM2 activates cancer-associated fibroblasts-like phenotype and affects chemo-resistance of liposarcoma cells against doxorubicin.Semantic proximity Read ↗

MDM2-p53 in liposarcoma: The need for targeted therapies with novel mechanisms of actionSemantic proximity Read ↗

FGFR2 is overexpressed in myxoid liposarcoma and inhibition of FGFR signaling impairs tumor growth in vitroSemantic proximity Read ↗

Comprehensive Immuno-Molecular Profiles for Liposarcoma: Roles of Programmed Death Ligand 1, Microsatellite Instability, and PIK3CA.Semantic proximity Read ↗

Prognostic Implications of MDM2 and CDK4 Co-amplification in Liposarcoma: Insights from FISH analysis for Translational OncologySemantic proximity Read ↗

Novel Therapeutic Insights in Dedifferentiated Liposarcoma: A Role for FGFR and MDM2 Dual TargetingSemantic proximity Read ↗

Activity of sunitinib in extraskeletal myxoid chondrosarcoma.Semantic proximity Read ↗

Delayed use of eribulin in a heavily pretreated liposarcoma patient, previously misdiagnosed as leiomyosarcoma.Semantic proximity Read ↗

Efficacy of Trabectedin in Patients with Advanced Translocation-Related Sarcomas: Pooled Analysis of Two Phase II StudiesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.